About this trial
The aim is to study whether the microbiota of children who are exposed to antibiotics at birth could be modified by synbiotic supplement and thereby reduce the risk of obesity, chronic diseases and respiratory tract infections. A total of 125 mother-child pairs will be recruited in this randomized, double-blind, placebo-controlled study. Infants are randomized to receive either a synbiotic supplement or a placebo for 2 months, after which their growth and morbidity will be monitored at the research clinic for 2 years.
Eligibility criteria
Qualifiers
None
Disqualifiers
Chorioamnionitis
Pre-eclampsia and hepatogestosis
Suspected malformation or serious condition of the foetus and neonates
Serious infection or other conditions not permitting breast milk feeding
Trial design
Treatments tested in this trial
- Synbiotic Supplement
- Placebo
Treatment groups
Sponsors and collaborators
Turku University Hospital
Lead sponsor
Lallemand Health Solutions
Collaborator